Beyond Air™ Schedules First Fiscal Quarter 2020 Financial Results Conference Call and Webcast

Conference Call & Webcast
Wednesday, August 14th @ 4:30 pm Eastern Time
Domestic: 877-407-0784
International: 201-689-8560
Passcode: 13692522
Webcast: http://public.viavid.com/index.php?id=135344

 

Beyond Air™ Announces New NASDAQ Ticker Symbol is XAIR

Beyond Air, Inc. announced that it has changed its NASDAQ ticker symbol from AITB to XAIR. The change is effective July 15, 2019.

 

CORRECTING and REPLACING – AIT Therapeutics Reports Financial Results for Fiscal Fourth Quarter and Year-End 2019 Results

  • Announces name change to Beyond Air™
  • Completed uplisting to the NASDAQ and $7.96 million PIPE financing
  • Anticipate PMA submission in the third quarter of calendar 2019
  • Anticipate CE Mark in the first half of calendar 2020
  • Announced licensing agreement with Circassia Pharmaceuticals for commercial rights for hypoxic respiratory failure in the hospital setting in the United States and China
  • Strengthened management team with key hires
  • Conference Call scheduled for June 25 at 4:30 pm Eastern Time

 

AIT Therapeutics Schedules Fiscal Year 2019 Financial Results Conference Call and Webcast

AIT Therapeutics, Inc. announced it will report financial results for its fiscal year ended March 31, 2019 after the market close on Tuesday, June 25, and will host a conference call and webcast at 4:30 pm Eastern Time.

 

AIT Therapeutics Announces $8 Million PIPE Financing

AIT Therapeutics, Inc. announced that it has successfully executed funding agreements to raise $8 million through a private investment in public equity (PIPE) financing. AIT will issue 1.6 million unregistered shares of common stock to investors at a purchase price of $5.00 per share. Proceeds from the raise will be used to continue development of the company’s three indications: Persistent Pulmonary Hypertension of the Newborn (PPHN), Bronchiolitis (BRO), and Nontuberculous mycobacteria (NTM), as well as for general corporate purposes.

“I would like to thank those who have taken the time to investigate what we at AIT have created over the past 30 months with our proprietary nitric oxide generator and delivery system technology and to understand the significant value creation for both patients and shareholders that will come with our continued execution over the next 18 months,” said Steve Lisi, Chairman and CEO of AIT. “This transaction will provide the funds needed to achieve our goals over the next 12 to 15 months of a PMA submission/FDA approval decision for PPHN, completion of our bronchiolitis trial this winter and the commencement of our at-home study in patients suffering from NTM lung infection.”

 

AIT Therapeutics to Participate at Jefferies 2019 Global Healthcare Conference

AIT Therapeutics, Inc. announced that Steven Lisi, CEO, will participate at the Jefferies 2019 Global Healthcare Conference being held at the Grand Hyatt in New York on June 4-7, 2019.

 

AIT Therapeutics Announces Study Published in Journal of Cystic Fibrosis

AIT Therapeutics, Inc. announced the study, authored by Professor Lea Bentur, Director, Pediatric Pulmonary Institute, Rambam Medical Center, Haifa Israel, entitled, “Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection,” was published in the Journal of Cystic Fibrosis.

“We achieved our goal of demonstrating the safety and tolerability of inhaled nitric oxide in cystic fibrosis patients with Mycobacterium abscessus lung infection and determined that further evaluation is warranted given the improvement shown in mean lung function, quality of life, physical function and M. abscessus load as shown by a downward trend in the sputum M. abscessus load measured during the study,” said Dr. Lea Bentur. “The study was not powered to demonstrate statistical significance, but we believe intermittent NO at 160ppm has the potential to demonstrate meaningful benefits to patients with cystic fibrosis where currently M. abscessus is an incurable chronic infection in most CF patients.”

 

AIT Therapeutics Presents On-Demand Nitric Oxide Study and Poster at the International Society for Aerosols in Medicine 2019 Congress in Montreux, Switzerland

AIT Therapeutics, Inc. presented data from its study: “On-Demand Nitric Oxide for Ventilator-Based Nitric Oxide Inhalation: A Risk-Reduction Perspective.” The study was presented as part of a session on pulmonary hypertension at the International Society for Aerosols in Medicine (ISAM) 2019 Congress in Montreux, Switzerland.

“This study clearly shows the safety benefits of on-demand NO and we believe our ventilator-compatible Nitric Oxide Generator and Delivery System is the way of the future,” said Steve Lisi, Chairman and CEO. “Eliminating the need for high-pressure NO cylinders in the hospital setting can bring tangible benefits, and we look forward to providing hospitals with a cost-effective, risk-reducing solution.”

 

AIT Therapeutics Participating at the Oppenheimer MedTech Day on May 29

AIT Therapeutics, Inc. announced that Steven Lisi, CEO, will participate in the Oppenheimer MedTech Day being held at the Hilton Union Square hotel in San Francisco on May 29, 2019.

 

AIT Therapeutics Presents Data at the 2019 American Thoracic Society Conference in Dallas, TX

AIT Therapeutics, Inc. announced it presented data from its study, entitled: “Synergistic Effect of Nitric Oxide with Antibiotics Against Mycobacterium Abscessus in Vitro” at the 2019 American Thoracic Society (ATS) Conference being held on May 17-22, 2019 in Dallas, TX. The study was presented today, May 20, as part of a mini-symposium on “Advances in the Treatment of NTM.”

 

AIT Therapeutics Announces Uplisting to the Nasdaq Capital Market

AIT announced that the Company’s common shares have been approved for listing on the The Nasdaq Capital Market. Trading is expected to begin on Tuesday, May 7 under its existing symbol AITB.
“I would like to thank the Nasdaq team for allowing us to trade on their prestigious, globally recognized and trusted exchange,” said Steven Lisi, Chairman and Chief Executive Officer of AIT Therapeutics. “I am very proud of the team at AIT for getting us to this point and I am confident that we will continue to execute our strategy and launch our first product in the United States before the middle of 2020.”

 

AIT Therapeutics to Demonstrate NO Generator and Delivery System at Pediatric Academic Societies Meeting in Baltimore, MD on April 27-30

AIT Therapeutics to Participate at Two Investor Conferences in March

AIT Therapeutics Schedules Fiscal Third Quarter 2019 Financial Results Conference Call and Webcast

AIT Receives $3.15 Million Milestone Payment from Commercialization Partner Circassia Pharmaceuticals

AIT Enters into $32.5 million Commercial Licensing Agreement with Circassia Pharmaceuticals for Its Novel Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and China

AIT Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer

AIT Nearing Definitive Agreement to License Commercial Rights of Its Novel Ventilator Compatible Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and a Second Country

AIT Therapeutics Reports Financial Results for Fiscal Second Quarter 2019 

AIT Therapeutics to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

AIT Therapeutics Schedules Fiscal Second Quarter 2019 Financial Results Conference Call and Webcast

AIT Therapeutics Presented Its High-Dose Nitric Oxide In Vitro Data at the North American Cystic Fibrosis Conference

AIT Therapeutics to Present High-Dose Nitric Oxide In Vitro Data at the North American Cystic Fibrosis Conference

AIT Therapeutics to Present at the Ladenburg 4th Annual Healthcare Conference

AIT Therapeutics Presented Nitric Oxide Data at the European Respiratory Society International Congress 2018

AIT Therapeutics Announces $526,500 Sale of Common Stock To Institutional Investor, Lincoln Park Capital Fund

AIT Therapeutics to Present Nitric Oxide Data at Two Upcoming Scientific Conferences

AIT Therapeutics Schedules Fiscal First Quarter 2019 Financial Results Conference Call and Webcast

AIT Therapeutics Announces Human and In-Vitro Nitric Oxide Data to be Presented at the 3rd Annual World Bronchiectasis Conference

AIT Therapeutics Announces Change to Fiscal Year End and Financial Results Conference Call and Webcast for the Three Months Ended March 31, 2018

AIT Therapeutics Presented Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex (MABSC) at the 2018 American Thoracic Society Conference

AIT Therapeutics Reports Year End 2017 Financial Results

AIT Therapeutics to Present Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex at the 2018 American Thoracic Society Conference

AIT Therapeutics Announces Year End 2017 Financial Results Conference Call and Webcast

AIT Therapeutics to Present at Two Investor Conferences

AIT Therapeutics to Hold Clinical Update Meeting – November 28, 2017 at 7:30 am ET

AIT Therapeutics Reports Third Quarter 2017 Financial Results

AIT Therapeutics webcast for the Ladenburg Thalmann 2017 Healthcare Conference

AIT Therapeutics Reports Second Quarter 2017 Financial Results

For Investor Relations enquiry, please email IR[at]ait-pharm.com, for Business Development and other matters, email BD[at]ait-pharm.com